Advertisement
CERS vs PACB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and PACB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 0 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).
- CERS’s FA Score: 0 green, 5 red.
- PACB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 2 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).
- CERS’s TA Score: 2 bullish, 6 bearish.
- PACB’s TA Score: 4 bullish, 5 bearish.
Price Growth
CERS (@Medical/Nursing Services) experienced а -4.72% price change this week, while PACB (@Medical/Nursing Services) price change was +1.50% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.73%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +3.98%.
Reported Earning Dates
CERS is expected to report earnings on Oct 30, 2025.
PACB is expected to report earnings on Nov 10, 2025.
Industries' Descriptions
@Medical/Nursing Services (-1.73% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| CERS | PACB | CERS / PACB | |
| Capitalization | 232M | 406M | 57% |
| EBITDA | -8.5M | -232.04M | 4% |
| Gain YTD | -21.429 | -26.230 | 82% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 185M | 152M | 122% |
| Total Cash | 80.9M | 343M | 24% |
| Total Debt | 99.4M | 699M | 14% |
CERS | PACB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 87 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 77 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (35) in the Medical Specialties industry is somewhat better than the same rating for PACB (100) in the Biotechnology industry. This means that CERS’s stock grew somewhat faster than PACB’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that CERS’s stock grew similarly to PACB’s over the last 12 months.
CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as PACB (99) in the Biotechnology industry. This means that CERS’s stock grew similarly to PACB’s over the last 12 months.
PACB's Price Growth Rating (60) in the Biotechnology industry is in the same range as CERS (87) in the Medical Specialties industry. This means that PACB’s stock grew similarly to CERS’s over the last 12 months.
PACB's P/E Growth Rating (77) in the Biotechnology industry is in the same range as CERS (100) in the Medical Specialties industry. This means that PACB’s stock grew similarly to CERS’s over the last 12 months.
| CERS | PACB | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 70% |
| Stochastic ODDS (%) | 4 days ago 85% | 4 days ago 84% |
| Momentum ODDS (%) | 4 days ago 82% | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 86% | 4 days ago 83% |
| TrendWeek ODDS (%) | 4 days ago 85% | 4 days ago 84% |
| TrendMonth ODDS (%) | 4 days ago 82% | 4 days ago 89% |
| Advances ODDS (%) | 20 days ago 76% | 20 days ago 86% |
| Declines ODDS (%) | 4 days ago 84% | 5 days ago 90% |
| BollingerBands ODDS (%) | N/A | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 86% | 4 days ago 85% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MCGRX | 16.91 | 0.14 | +0.83% |
| BlackRock Natural Resources Inv C | |||
| LMPEX | 27.32 | 0.22 | +0.81% |
| Franklin Global Equity 1 | |||
| FCDTX | 34.63 | 0.14 | +0.41% |
| Fidelity Advisor Stock Selector Sm Cp M | |||
| WSMDX | 26.15 | 0.06 | +0.23% |
| William Blair Small-Mid Cap Growth I | |||
| SBQAX | 13.79 | -0.01 | -0.07% |
| AmericaFirst Alpha Trends Factor Class A | |||
CERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | -2.42% | ||
| LAB - CERS | 46% Loosely correlated | +1.16% | ||
| UTMD - CERS | 45% Loosely correlated | +1.10% | ||
| BLFS - CERS | 45% Loosely correlated | N/A | ||
| NNOX - CERS | 45% Loosely correlated | +0.65% | ||
| PACB - CERS | 44% Loosely correlated | +7.14% | ||
More | ||||
PACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PACB has been loosely correlated with LAB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then LAB could also see price increases.
| Ticker / NAME | Correlation To PACB | 1D Price Change % | ||
|---|---|---|---|---|
| PACB | 100% | +7.14% | ||
| LAB - PACB | 53% Loosely correlated | +1.16% | ||
| AZTA - PACB | 47% Loosely correlated | -0.34% | ||
| ILMN - PACB | 46% Loosely correlated | -0.98% | ||
| TWST - PACB | 44% Loosely correlated | +2.56% | ||
| CERS - PACB | 39% Loosely correlated | -2.42% | ||
More | ||||